It is worth pointing out that in this study, a decreased nuclear PPARγ expression was detected in the breast tumor tissue of patients treated with rosiglitazone, suggesting the rosiglitazone-mediated effects on breast cancer cell signaling [45]. Here, PPARG is linked to breast neoplasm.